Chinese expert consensus on management of kidney injury in liver transplant recipients (2017 edition)

doi:10.3877/cma.j.issn.1674-3903.2017.03.002

Abstract

Chinese College of transplant Doctors, Section of Liver Transplantation, Society of Organ Transplantation, Chinese Medical Association. Chinese expert consensus on management of kidney injury in liver transplant recipients (2017 edition)[J]. Chinese Journal of Transplantation(Electronic Edition), 2017, 11(03): 130-137.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhyzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3903.2017.03.002

https://zhyzzz.cma-cmc.com.cn/EN/Y2017/V11/I03/130

Figures/Tables 2

References 94

1	Kim WR,Lake JR,Smith JM, et al. OPTN/SRTR 2013 Annual Data Report: liver[J]. Am J Transplant, 2015, 15(Suppl 2): 1-28.
2	Wang H,Jiang W,Zhou Z, et al. Liver transplantation in mainland China: the overview of CLTR 2011 annual scientific report[J]. Hepatobiliary Surg Nutr, 2013, 2(4): 188-197.
3	Watt KD,Pedersen RA,Kremers WK, et al. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study[J]. Am J Transplant, 2010, 10(6): 1420-1427.
4	Levitsky J,O'Leary JG,Asrani S, et al. Protecting the kidney in liver transplant recipients: Practice-based recommendations from the American Society of Transplantation Liver and Intestine Community of Practice[J]. Am J Transplant, 2016, 16(9): 2532-2544.
5	Rossi AP,Vella JP. Acute kidney disease after liver and heart transplantation[J]. Transplantation, 2016, 100(3): 506-514.
6	Lucey MR,Terrault N,Ojo L, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation[J]. Liver Transpl, 2013, 19(1): 3-26.
7	Ojo AO,Held PJ,Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ[J]. N Engl J Med, 2003, 349(10): 931-940.
8	Gonwa TA,Mai ML,Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment[J]. Transplantation, 2001, 72(12): 1934-1939.
9	Fabrizi F,Dixit V,Martin P, et al. Chronic kidney disease after liver transplantation: Recent evidence[J]. Int J Artif Organs, 2010, 33(11): 803-811.
10	McGuire BM,Rosenthal P,Brown CC, et al. Long-term management of the liver transplant patient: recommendations for the primary care doctor[J]. Am J Transplant, 2009, 9(9): 1988-2003.
11	Allen AM,Kim WR,Therneau TM, et al. Chronic kidney disease and associated mortality after liver transplantation-a time-dependent analysis using measured glomerular filtration rate[J]. J Hepatol, 2014, 61(2): 286-292.
12	Parajuli S,Foley D,Djamali A, et al. Renal function and transplantation in liver disease[J]. Transplantation, 2015, 99(9): 1756-1764.
13	Khwaja A. KDIGO clinical practice guidelines for acute kidney injury[J]. Nephron Clin Pract, 2012, 120(4): c179-c184.
14	KDIGO Outcomes. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease[J]. Kidney Int Suppl, 2013, 3(1): 1-150.
15	Pham PT,Lunsford KE,Bunnapradist S, et al. Simultaneous liver-kidney transplantation or liver transplantation alone for patients in need of liver transplantation with renal dysfunction[J]. Curr Opin Organ Transplant, 2016, 21(2): 194-200.
16	Moreau R,Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD[J]. Hepatology, 2003, 37(2): 233-243.
17	Angeli P,Gines P,Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites[J]. Gut, 2015, 64(4): 531-537.
18	Hilmi IA,Damian D,Al-Khafaji A, et al. Acute kidney injury following orthotopic liver transplantation: incidence, risk factors, and effects on patient and graft outcomes[J]. Br J Anaesth, 2015, 114(6): 919-926.
19	Cabezuelo JB,Ramirez P,Rios A, et al. Risk factors of acute renal failure after liver transplantation[J]. Kidney Int, 2006, 69(6): 1073-1080.
20	Zhu M,Li Y,Xia Q, et al. Strong impact of acute kidney injury on survival after liver transplantation[J]. Transplant Proc, 2010, 42(9): 3634-3638.
21	Barreto AG,Daher EF,Silva Junior GB, et al. Risk factors for acute kidney injury and 30-day mortality after liver transplantation[J]. Ann Hepatol, 2015, 14(5): 688-694.
22	Klaus F,Keitel da Silva C,Meinerz G, et al. Acute kidney injury after liver transplantation: incidence and mortality[J]. Transplant Proc, 2014, 46(6): 1819-1821.
23	Shao ZY,Yan LN,Wang WT, et al. Prophylaxis of chronic kidney disease after liver transplantation-experience from west China[J]. World J Gastroenterol, 2012, 18(9): 991-998.
24	Bellomo R,Ronco C,Kellum JA, et al. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group[J]. Crit Care, 2004, 8(4): R204-R212.
25	Patel HK,Patel A,Abouljoud M, et al. Survival after liver transplantation in patients who develop renal insufficiency[J]. Transplant Proc, 2010, 42(10): 4167-4170.
26	Francoz C,Glotz D,Moreau R, et al. The evaluation of renal function and disease in patients with cirrhosis[J]. J Hepatol, 2010, 52(4): 605-613.
27	Skluzacek PA,Szewc RG,Nolan CR 3rd, et al. Prediction of GFR in liver transplant candidates[J]. Am J Kidney Dis, 2003, 42(6): 1169-1176.
28	Teneva BH. Pathogenesis and assessment of renal function in patients with liver cirrhosis[J]. Folia Med (Plovdiv), 2012, 54(4): 5-13.
29	De Souza V,Hadj-Aissa A,Dolomanova O, et al. Creatinine- versus cystatine C-based equations in assessing the renal function of candidates for liver transplantation with cirrhosis[J]. Hepatology, 2014, 59(4): 1522-1531.
30	Adachi M,Tanaka A,Aiso M, et al. Benefit of cystatin C in evaluation of renal function and prediction of survival in patients with cirrhosis[J]. Hepatol Res, 2015, 45(13): 1299-1306.
31	Beben T,Rifkin DE. GFR estimating equations and liver disease[J]. Adv Chronic Kidney Dis, 2015, 22(5): 337-342.
32	Uguen T,Jezequel C,Ropert M, et al. Pretransplant renal function according to CKD-EPI cystatin C equation is a prognostic factor of death after liver transplantation[J]. Liver Int, 36(4): 547-554.
33	Allen AM,Kim WR,Larson JJ, et al. Serum cystatin C as an indicator of renal function and mortality in liver transplant recipients[J]. Transplantation, 2015, 99(7): 1431-1435.
34	Ling Q,Xu X,Li J, et al. A new serum cystatin C-based equation for assessing glomerular filtration rate in liver transplantation[J]. Clin Chem Lab Med, 2008, 46(3): 405-410.
35	Tan HK,Marquez M,Wong F, et al. Pretransplant type 2 hepatorenal syndrome is associated with persistently impaired renal function after liver transplantation[J]. Transplantation, 2015, 99(7): 1441-1446.
36	Ruebner R,Goldberg D,Abt PL, et al. Risk of end-stage renal disease among liver transplant recipients with pretransplant renal dysfunction[J]. Am J Transplant, 2012, 12(11): 2958-2965.
37	Longenecker JC,Estrella MM,Segev DL, et al. Patterns of kidney function before and after orthotopic liver transplant: associations with length of hospital stay, progression to end-stage renal disease, and mortality[J]. Transplantation, 2015, 99(12): 2556-2564.
38	Bahirwani R,Forde KA,Mu Y, et al. End-stage renal disease after liver transplantation in patients with pre-transplant chronic kidney disease[J]. Clin Transplant, 2014, 28(2): 205-210.
39	Calmus Y,Conti F,Cluzel P, et al. Prospective assessment of renal histopathological lesions in patients with end-stage liver disease: effects on long-term renal function after liver transplantation[J]. J Hepatol, 2012, 57(3): 572-576.
40	EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis[J]. J Hepatol, 2010, 53(3): 397-417.
41	Rodriguez E,Henrique Pereira G,Sola E, et al. Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes[J]. Liver Transpl, 2015, 21(11): 1347-1354.
42	Pham PT,Pham PC,Danovitch GM. Renal failure in adult liver transplant recipients//Busuttil RW, Klintmalm GB, editors. Transplantation of the liver, 3rd ed[M]. Philadelphia, PA: Elsevier Saunders, 2015: 934-959.
43	Xu X,Ling Q,Zhang M, et al. Outcome of patients with hepatorenal syndrome type 1 after liver transplantation: Hangzhou experience[J]. Transplantation, 2009, 87(10): 1514-1519.
44	Kiberd B,Skedgel C,Alwayn I, et al. Simultaneous liver kidney transplantation: a medical decision analysis[J]. Transplantation, 2011, 91(1): 121-127.
45	Davis CL,Feng S,Sung R, et al. Simultaneous liver-kidney transplantation: evaluation to decision making[J]. Am J Transplant, 2007, 7(7): 1702-1709.
46	Eason JD,Gonwa TA,Davis CL, et al. Proceedings of consensus conference on simultaneous liver kidney transplantation(SLK)[J]. Am J Transplant, 2008, 8(11): 2243-2251.
47	Nadim MK,Sung RS,Davis CL, et al. Simultaneous liver-kidney transplantation summit: current state and future directions[J]. Am J Transplant, 2012, 12(11): 2901-2908.
48	Durand F,Graupera I,Gines P, et al. Pathogenesis of hepatorenal syndrome: implications for therapy[J]. Am J Kidney Dis, 2016, 67(2): 318-328.
49	中华医学会外科学分会器官移植学组. 肝移植受者肾功能损伤诊疗指南[J/CD]. 中华移植杂志：电子版, 2011, 5(3): 60-62.
50	Lewandowska L,Matuszkiewicz-Rowinska J. Acute kidney injury after procedures of orthotopic liver transplantation[J]. Ann Transplant, 2011, 16(2): 103-108.
51	Sang BH,Bang JY,Song JG, et al. Hypoalbuminemia within two postoperative days is an independent risk factor for acute kidney injury following living donor liver transplantation: a propensity score analysis of 998 consecutive patients[J]. Crit Care Med, 2015, 43(12): 2552-2561.
52	Smoter P,Nyckowski P,Grat M, et al. Risk factors of acute renal failure after orthotopic liver transplantation: single-center experience[J]. Transplant Proc, 2014, 46(8): 2786-2789.
53	Leithead JA,Armstrong MJ,Corbett C, et al. Hepatic ischemia reperfusion injury is associated with acute kidney injury following donation after brain death liver transplantation[J]. Transpl Int., 2013, 26(11): 1116-1125.
54	Laing RW,Scalera I,Isaac J, et al. Liver transplantation using grafts from donors after circulatory death: A propensity-matched study from a single centre[J]. Am J Transplant, 2016, 16(6): 1795-1804.
55	Xu X,Ling Q,Wei Q, et al. An effective model for predicting acute kidney injury after liver transplantation[J]. Hepatobiliary Pancreat Dis Int, 2010, 9(3): 259-263.
56	Wilson T,Quan S,Cheema K, et al. Risk prediction models for acute kidney injury following major noncardiac surgery: systematic review[J]. Nephrol Dial Transplant, 2016, 31(2): 231-240.
57	Kim JM,Jo YY,Na SW, et al. The predictors for continuous renal replacement therapy in liver transplant recipients[J]. Transplant Proc, 2014, 46(1): 184-191.
58	Sanchez EQ,Gonwa TA,Levy MF, et al. Preoperative and perioperative predictors of the need for renal replacement therapy after orthotopic liver transplantation[J]. Transplantation, 2004, 78(7): 1048-1054.
59	Rueggeberg A,Boehm S,Napieralski F, et al. Development of a risk stratification model for predicting acute renal failure in orthotopic liver transplantation recipients[J]. Anaesthesia, 2008, 63(11): 1174-1180.
60	Ziolkowski J,Paczek L,Senatorski G, et al. Renal function after liver transplantation: calcineurin inhibitor nephrotoxicity[J]. Transplant Proc, 2003, 35(6): 2307-2309.
61	Porayko MK,Textor SC,Krom RA, et al. Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation[J]. Mayo Clin Proc, 1994, 69(2): 105-111.
62	Platz KP,Mueller AR,Blumhardt G, et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506[J]. Transplantation, 1994, 58(2): 170-178.
63	Issa N,Kukla A,Ibrahim HN. Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence[J]. Am J Nephrol, 2013, 37(6): 602-612.
64	Flechner SM,Kobashigawa J,Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity[J]. Clin Transplant, 2008, 22(1): 1-15.
65	Kniepeiss D,Iberer F,Grasser B, et al. Sirolimus in patients after liver transplantation[J]. Transplant, 2003, 35(2): 815-816.
66	Fischer L,Saliba F,Kaiser GM, et al. Three-year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus: follow-up results from a randomized, multicenter study[J]. Transplantation, 2015, 99(7): 1455-1462.
67	Saliba F,De Simone P,Nevens F, et al. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study[J]. Am J Transplant, 2013, 13(7): 1734-1745.
68	De Simone P,Nevens F,De Carlis L, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial[J]. Am J Transplant, 2012, 12(11): 3008-3020.
69	Nashan B,Schemmer P,Braun F, et al. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial[J]. Trials, 2015, 16: 118.
70	谢琴芬,郑树森. 肝癌患者肝移植后的免疫抑制剂应用[J]. 中华器官移植杂志, 2013, 34(9): 573-575.
71	Neuberger JM,Mamelok RD,Neuhaus P, et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT’ study[J]. Am J Transplant, 2009, 9(2): 327-336.
72	Boudjema K,Camus C,Saliba F, et al. Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study[J]. Am J Transplant, 2011, 11(5): 965-976.
73	Evans HM,McKiernan PJ,Kelly DA. Mycophenolate mofetil for renal dysfunction after pediatric liver transplantation[J]. Transplantation, 2005, 79(11): 1575-1580.
74	Martín-Mateos RM,Graus J,Albillos A, et al. Initial immunosuppression with or without basiliximab: a comparative study[J]. Transplant Proc, 2012, 44(9): 2570-2572.
75	Coca SG,Yusuf B,Shlipak MG, et al. Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis[J]. Am J Kidney Dis, 2009, 53(6): 961-973.
76	Parikh NI,Hwang SJ,Larson MG, et al. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control[J]. Arch Intern Med, 2006, 166(17): 1884-1891.
77	Hsu CY. Linking the population epidemiology of acute renal failure, chronic kidney disease and end-stage renal disease[J]. Curr Opin Nephrol Hypertens, 2007, 16(3): 221-226.
78	Hsu CY,Chertow GM,McCulloch CE, et al. Nonrecovery of kidney function and death after acute on chronic renal failure[J]. Clin J Am Soc Nephrol, 2009, 4(5): 891-898.
79	Goldstein SL,Jaber BL,Faubel S, et al. AKI transition of care: a potential opportunity to detect and prevent CKD[J]. Clin J Am Soc Nephrol, 2013, 8(3): 476-483.
80	Burra P,Senzolo M,Masier A, et al. Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study[J]. Dig Liver Dis, 2009, 41(5): 350-356.
81	Lee JP,Heo NJ,Joo KW, et al. Risk factors for consequent kidney impairment and differential impact of liver transplantation on renal function[J]. Nephrology Dialysis Transplantation, 2010, 25(8): 2772-2785.
82	中国医师协会器官移植医师分会, 中华医学会外科学分会器官移植学组, 中华医学会器官移植学分会肝移植学组. 中国肝移植受者代谢病管理专家共识(2015版)[J]. 中华消化外科杂志, 2015, 14(8): 601-605.
83	Cattaneo D,Perico N,Gaspari F, et al. Nephrotoxic aspects of cyclosporine[J]. Transplant Proc, 2004, 36(2 Suppl): 234S-239S.
84	Campbell MS,Rai J,Kozin E, et al. Effects of sirolimus vs. calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation[J]. Clin Transplant, 2007, 21(3): 377-384.
85	DuBay D,Smith RJ,Qiu KG, et al. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens[J]. Liver Transpl, 2008, 14(5): 651-659.
86	Abdelmalek MF,Humar A,Stickel F, et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial[J]. Am J Transplant, 2012, 12(3): 694-705.
87	Stallone G,Infante B,Pontrelli P, et al. Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins[J]. Transplantation, 2011, 91(9): 997-1004.
88	Cai Y,Chen Y,Zheng S, et al. Sirolimus damages podocytes in rats with protein overload nephropathy[J]. J Nephrol, 2011, 24(3): 307-312.
89	Wadei HM,Zaky ZS,Keaveny AP, et al. Proteinuria following sirolimus conversion is associated with deterioration of kidney function in liver transplant recipients[J]. Transplantation, 2012, 93(10): 1006-1012.
90	赖威,卢实春,王孟龙, 等. 钙调磷酸酶抑制剂减量的吗替麦考酚酯免疫抑制方案对改善肝移植术后肾损害的影响[J]. 中华医学杂志, 2009, 89(22): 1529-1532.
91	Farkas SA,Schnitzbauer AA,Kirchner G, et al. Calcineurin inhibitor minimization protocols in liver transplantation[J]. Transpl Int, 2009, 22(1): 49-60.
92	Dharancy S,Iannelli A,Hulin A, et al. Mycophenolate mofetil monotherapy for severe side effects of calcineurin inhibitors following liver transplantation[J]. Am J Transplant, 2009, 9(3): 610-613.
93	Tannuri U,Gibelli NE,Maksoud-Filho JG, et al. Mycophenolate mofetil promotes prolonged improvement of renal dysfunction after pediatric liver transplantation: experience of a single center[J]. Pediatr Transplant, 2007, 11(1): 82-86.
94	Demirci G,Becker T,Nyibata M, et al. Results of combined and sequential liver-kidney transplantation[J]. Liver Transpl, 2003, 9(10): 1067-1078.

分级	血清肌酐	尿量
1级	1.5～1.9倍基线值，或升高值≥26.5 μmol/L	连续6～12 h<0.5 mL/(kg·h)
2级	2.0～2.9倍基线值	连续12 h以上<0.5 mL/(kg·h)
3级	≥3.0倍基线值，或升高值≥353.6 μmol/L，或开始行肾脏替代治疗，或年龄<18岁患者估算肾小球滤过率<35 mL/(min·1.73 m²)	连续24 h以上<0.3 mL/(kg·h)或无尿12 h

分级	血清肌酐	尿量
1级	1.5～1.9倍基线值，或升高值≥26.5 μmol/L	连续6～12 h<0.5 mL/(kg·h)
2级	2.0～2.9倍基线值	连续12 h以上<0.5 mL/(kg·h)
3级	≥3.0倍基线值，或升高值≥353.6 μmol/L，或开始行肾脏替代治疗，或年龄<18岁患者估算肾小球滤过率<35 mL/(min·1.73 m²)	连续24 h以上<0.3 mL/(kg·h)或无尿12 h

GFR分期	GFR(mL/min·1.73 m²)	描述
G1期	≥90	正常或偏高
G2期	60～89	轻度下降^a
G3a期	45～59	轻-中度下降
G3b期	30～44	中-重度下降
G4期	15～29	重度下降
G5期	<15	肾衰竭

GFR分期	GFR(mL/min·1.73 m²)	描述
G1期	≥90	正常或偏高
G2期	60～89	轻度下降^a
G3a期	45～59	轻-中度下降
G3b期	30～44	中-重度下降
G4期	15～29	重度下降
G5期	<15	肾衰竭

Please choose a citation manager

Content to export

Chinese expert consensus on management of kidney injury in liver transplant recipients (2017 edition)

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 2

References 94

Related Articles 0

Recommended Articles

Metrics

Comments

模态框（Modal）标题

Please choose a citation manager

Content to export

Chinese expert consensus on management of kidney injury in liver transplant recipients (2017 edition)

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 2

References 94

Related Articles 0

Recommended Articles

Metrics

Comments